To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer | MicrobiomeTrials
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2016-12-13Est. Completion: 2026-12-31
Enrollment target: 200 participants
Locations
Massachusetts General Hospital., Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Columbia University Medical Center, New York, New York, United States
SCRI Oncology Partners, Nashville, Tennessee, United States
Princess Margaret Hospital, Toronto, Ontario, Canada